SEC Form 4 · accession 0001214659-19-001354
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie A Donadio
Officer — Sr. VP, CFO
Period of report
Feb 15, 2019
Accepted (ET)
Feb 19, 2019 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 15, 2019 | M | 7,500 | $5.40 | A | 7,721 | D | |
| Common StockF2 | Feb 15, 2019 | S | 7,500 | $75.0002 | D | 221 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $5.40 | Feb 15, 2019 | M | 7,500 | D | — | Jan 25, 2027 | Common Stock | 7,500 | 30,000 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June14, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $75.00 to $75.015. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F31/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.